Intranasal kennel cough vaccine protecting dogs from experimental <i>Bordetella bronchiseptica</i> challenge within 72 hours

Gore, Thomas C.; Headley, Mark B.; Laris, R.; Bergman, J. G. H. E.; Sutton, David; Horspool, L. J. I.; Jacobs, A. A. C.

doi:10.1136/vr.156.15.482

Cited by 19 publications

(9 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[56] In another study, the vaccine was shown to induce protective immunity 72 h postvaccination. [57] Although the reason for the rapid onset of immunity was not determined within the scope of that study, studies within the field of TB vaccination have shown that mucosal vaccines are able to provide non-specific immunity immediately after vaccination by stimulating innate immune responses at the mucosal surface (reviewed in Beverly et al [58] ), and it is possible that similar mechanisms were at play.…”

Section: Non-core Canine Infectious Respiratory Disease Vaccinationsmentioning

confidence: 93%

The challenges in developing effective canine infectious respiratory disease vaccines

Mitchell

Brownlie

2015

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives Canine infectious respiratory disease (CIRD) is a disease of multifactorial aetiology, where multiple pathogens act sequentially or synergistically to cause disease. It is common within large dog populations, such as those in re-homing or training kennels. Vaccines are vital in its management of CIRD, but they often fail to prevent disease. Recently, a number of novel pathogens have been identified in CIRD outbreaks and represent new targets for vaccination. Key findings Innate immune responses provide a vital first line of defence against the infectious agents involved in the development of CIRD. Once breeched, adaptive mucosal immunity is necessary to prevent infection and limit spread. Current vaccines target only a few of the agents involved in CIRD. Evidence, from the limited amount of published data, indicates that although vaccinating against these agents reduces infection rates, duration of shedding and severity of disease, it does not induce sterilising immunity; and this has important consequences for the management of the disease, and the future of CIRD vaccine development. Summary In the process of considering the development of novel CIRD vaccines, this paper focuses on the immunological mechanisms that provide protection for the respiratory tract, the current recommendations for canine vaccination, and the challenges surrounding existing CIRD vaccines, and their future development.

show abstract

Section: Non-core Canine Infectious Respiratory Disease Vaccinationsmentioning

confidence: 93%

The challenges in developing effective canine infectious respiratory disease vaccines

Mitchell

Brownlie

2015

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

“…34 Protection with intranasal vaccines also occurs in the face of maternal antibody and can last at least 1 year. Several avirulent live, mucosal (intranasal or oral) B. bronchiseptica vaccines are available for dogs, some of which also contain canine parainfluenza virus with or without canine adenovirus 2.…”

Section: Immunity and Vaccinationmentioning

confidence: 99%

Bordetellosis

Sykes¹

2014

Canine and Feline Infectious Diseases

View full text Add to dashboard Cite

“…Vaccines best considered against Bb infection in other species are live attenuated by intranasal or oral application: they induce both local immunity at nasal level (IgA) and seroconversion (IgG), only one application is needed to produce longtime immunity, effective immunity is achieved rapidly (up to 72 hours) and do not provoke local reactions [23][24][25][26][27][28][29][30][31]. Local nasal immunity (IgA) appears to be of crucial importance in respiratory infectious diseases, particularly if Bordetella spp.…”

Section: Vaccinesmentioning

confidence: 99%

Bordetella Bronchiseptica Vaccines in Pet Guinea Pigs? A Review of the Literature

Gallego¹

2017

SOJVS

View full text Add to dashboard Cite

Bordetella bronchiseptica causes severe respiratory disease in guinea pigs and it has been associated with stillbirths, abortions, infertility and infections of the reproductive system and tympanic bullae. Disease caused by Bordetella bronchiseptica in pet guinea pigs is mostly a poor understood disease; studies about this pathogen has been conducted mostly in laboratory guinea pigs. The objective of this review is to condense published information about the disease caused by Bordetella bronchiseptica in guinea pigs for the veterinarian who attends pet guinea pigs, with special emphasis on the prevention of this disease. The author concludes that vaccination in pet guinea pigs against Bordetella bronchiseptica needs to be considered for future studies. Received PathogenyBordetella bronchiseptica (Bb) is a gram-negative rod that has tropism for the ciliated respiratory epithelium. Infected pet guinea pigs can eliminate the bacteria, become asymptomatic carriers or develop the disease. The pet guinea pigs that develop the disease usually are attended at the veterinary clinic showing nasal and ocular discharge, respiratory sounds and dyspnea; the inappetence and lethargy indicate a poor prognosis. The diagnosis and treatment is based on deep nasal culture and antibiogram. Guinea pigs that have contact with the diseased guinea pig should be separated and occurrence of clinical signs should be monitorized at least until the diseased guinea pig has been cured. It is good practice to perform x-rays of the head and chest of the guinea pigs that are in contact with the diseased ones because a subclinical or early-stage disease can be detected [1][2][3].Bordetella bronchiseptica causes severe respiratory disease in guinea pigs, firstly described at the end of the 19th century [4] (Figure 1). Stillbirths, abortions, infertility and infections of the reproductive system can occur if haematonous spread of the bacteria develops; also the tympanic bullae may contain purulent exudates in affected animals due to ascending infection [1,5,6] (Figure 2,3). The incidence of Bb in a colony is usually 20% lower in laboratory animals if no action is taken, but this incidence is unknown in guinea pigs [7]. Disease caused by Bb in pet guinea pigs is mostly a poor understood disease because what is known of the disease is mostly by studies conducted in laboratory guinea pigs, and not in pet guinea pigs [1][2][3].

show abstract

Intranasal kennel cough vaccine protecting dogs from experimental Bordetella bronchiseptica challenge within 72 hours

Cited by 19 publications

References 2 publications

The challenges in developing effective canine infectious respiratory disease vaccines

The challenges in developing effective canine infectious respiratory disease vaccines

Bordetellosis

Bordetella Bronchiseptica Vaccines in Pet Guinea Pigs? A Review of the Literature

Contact Info

Product

Resources

About